Repositorio Institucional
Repositorio Institucional
CONICET Digital
  • Inicio
  • EXPLORAR
    • AUTORES
    • DISCIPLINAS
    • COMUNIDADES
  • Estadísticas
  • Novedades
    • Noticias
    • Boletines
  • Ayuda
    • General
    • Datos de investigación
  • Acerca de
    • CONICET Digital
    • Equipo
    • Red Federal
  • Contacto
JavaScript is disabled for your browser. Some features of this site may not work without it.
  • INFORMACIÓN GENERAL
  • RESUMEN
  • ESTADISTICAS
 
Artículo

Human serum albumin nanoparticles for ocular delivery of bevacizumab

Luis de Redín, Inés; Boiero, CarolinaIcon ; Martínez-Ohárriz, María Cristina; Agüeros, Maite; Ramos, Rocío; Peñuelas, Iván; Allemandi, Daniel AlbertoIcon ; Llabot, Juan ManuelIcon ; Irache, Juan M.
Fecha de publicación: 04/2018
Editorial: Elsevier Science
Revista: International Journal Of Pharmaceutics
ISSN: 0378-5173
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:
Otras Nanotecnología

Resumen

Bevacizumab-loaded nanoparticles (B-NP) were prepared by a desolvation process followed by freeze-drying, without any chemical, physical or enzymatic cross-linkage. Compared with typical HSA nanoparticles cross-linked with glutaraldehyde (B-NP-GLU), B-NP displayed a significantly higher mean size (310 nm vs. 180 nm) and a lower negative zeta potential (−15 mV vs. −36 mV). On the contrary, B-NP displayed a high payload of approximately 13% when measured by a specific ELISA, whereas B-NP-GLU presented a very low bevacizumab loading (0.1 μg/mg). These results could be related to the inactivation of bevacizumab after reacting with glutaraldehyde. From B-NP, bevacizumab was released following an initial burst effect, proceeded by a continuous release of bevacizumab at a rate of 6 μg/h. Cytotoxicity studies in ARPE cells were carried out at a single dose up to 72 h and with repeated doses over a 5-day period. Neither bevacizumab nor B-NP altered cell viability even when repeated doses were used. Finally, B-NP were labeled with 99mTc and administered as eye drops in rats. 99mTc-B-NP remained in the eye for at least 4 h while 99mTc-HSA was rapidly drained from the administration point. In summary, HSA nanoparticles may be an appropriate candidate for ocular delivery of bevacizumab.
Palabras clave: BEVACIZUMAB , CONTROLLED RELEASE , DESOLVATION , HUMAN SERUM ALBUMIN , NANOPARTICLES , OCULAR DELIVERY
Ver el registro completo
 
Archivos asociados
Thumbnail
 
Tamaño: 1.670Mb
Formato: PDF
.
Descargar
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/92602
URL: http://linkinghub.elsevier.com/retrieve/pii/S0378517318300838
DOI: https://doi.org/10.1016/j.ijpharm.2018.02.003
Colecciones
Articulos(UNITEFA)
Articulos de UNIDAD DE INVESTIGACION Y DESARROLLO EN TECNOLOGIA FARMACEUTICA
Citación
Luis de Redín, Inés; Boiero, Carolina; Martínez-Ohárriz, María Cristina; Agüeros, Maite; Ramos, Rocío; et al.; Human serum albumin nanoparticles for ocular delivery of bevacizumab; Elsevier Science; International Journal Of Pharmaceutics; 541; 1-2; 4-2018; 214-223
Compartir
Altmétricas
 

Enviar por e-mail
Separar cada destinatario (hasta 5) con punto y coma.
  • Facebook
  • X Conicet Digital
  • Instagram
  • YouTube
  • Sound Cloud
  • LinkedIn

Los contenidos del CONICET están licenciados bajo Creative Commons Reconocimiento 2.5 Argentina License

https://www.conicet.gov.ar/ - CONICET

Inicio

Explorar

  • Autores
  • Disciplinas
  • Comunidades

Estadísticas

Novedades

  • Noticias
  • Boletines

Ayuda

Acerca de

  • CONICET Digital
  • Equipo
  • Red Federal

Contacto

Godoy Cruz 2290 (C1425FQB) CABA – República Argentina – Tel: +5411 4899-5400 repositorio@conicet.gov.ar
TÉRMINOS Y CONDICIONES